DUBLIN, Mar. 19, 2015 /PRNewswire/ --Research and Markets
(http://www.researchandmarkets.com/research/32p997/inhaled_drug) has announced the addition of the "Inhaled Drug Delivery to 2022" report to their offering.
The upper airway diseases Asthma and COPD remain significant health challenges for both patients and clinicians. Inhalers that combine two drugs indicated for treating upper airway diseases in one inhaler are gaining interest due to the complementary therapeutic effects of certain classes of drugs when taken together. Systemic delivery continues to represent an area of significant opportunity. Products and product candidates in this category include inhaled drugs for the treatment of such diverse conditions as pulmonary arterial hypertension, neurological disorders, hereditary diseases and pain management.
Key Topics Covered:
1.Executive Summary
2. The Orally Inhaled Drug Delivery Market
- Therapeutic Targets
- Upper Respiratory
- Systemic Inhaled Delivery
- Demand Drivers
- Risk Factors
3. Competing Technologies
- Dry Powder Inhalers
- Metered Dose Inhalers
- Nebulizers
4. Inhalation Technology & Product Development Factors
- Formulation Factors
- Drug Formulations
- Formulation Technologies
- Excipients and Release Profiles
5. Inhalation Device Design Factors
- Dry Powder Inhalers
- Metered Dose Inhalers
- Nebulizers
6. Inhaler Performance Factors
- Bioavailability
- Dose Reproducibility
- Active Compound Stability
- Testing and Packaging
7. Inhalation Devices - Product & Device Assessments
- Dry Powder inhalers
- Metered Dose Inhalers
- Nebulizers
8. Inhaled Drugs - Therapeutic Segment Analysis & Forecasts
- Upper Respiratory Indications
- Asthma
- COPD
- Systemic Drug Delivery
- Bioterror
- Cardiovascular Medicine
- Pulmonary Hypertension
- Diabetes
- Hereditary Diseases
- Cystic Fibrosis
- Immunology
- Infectious Diseases
- Osteoporosis
- Neurology
- Oncology
9. Market Factors
- Regulatory Issues
- Patient Compliance
- Healthcare Economics
- Connected Devices
10. Market Sector Company Profiles
For more information visit http://www.researchandmarkets.com/research/32p997/inhaled_drug
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article